The bioinformatics industry in the Nordics is a vibrant sector blending biology, computer science, and data analysis. Companies range from startups to established firms, focusing on developments in precision medicine, genomics, and drug discovery. With a surge in computational biology and machine learning applications, Nordic bioinformatics firms are pushing the envelope on healthcare innovations. Notably, strong government support and collaboration between academic institutions fuel growth in biopharma and biotechnology, emphasizing health data utilization. There is also increasing interest in personalized treatments, making bioinformatics vital for future medical advancements across the region.


The list comprises 18 noteworthy investors in the Nordic bioinformatics sector, spanning various categories including venture capital and private equity. Headquartered in cities like Stockholm, Copenhagen, and Oslo, these firms vary in size from small teams to larger organizations, each with a specific focus on healthcare and technology. Founded between the late 1990s and recent years, they have collectively executed over 100 investments in 2024, showcasing an active involvement in the growth of bioinformatics startups. With different investment strategies and technological influences, these investors play a crucial role in shaping the industry’s future.


Top 18 Bioinformatics Investors in the Nordics


1. Novo Holdings

  • Website: novoholdings.dk
  • Type: Venture Capital
  • Headquarters: Hellerup, Denmark
  • Founded year: 1999
  • Headcount: 51-200
  • Number of deals in 2024: 45
  • LinkedIn: novo-a-s

Novo Holdings A/S is a not-for-profit investment firm based in Hellerup, Denmark, founded in 1999. It manages the assets of the Novo Nordisk Foundation and is dedicated to investing in life science companies at various stages of development. Novo Holdings provides capital and strategic support to enhance healthcare solutions. Notably, they have invested in Tempus, a company that leverages data and technology to improve cancer care, raising significant funds in multiple rounds, including a $200 million Series G and a $250 million debt financing in December 2020. Additionally, they led a $70 million Series C financing round for Mission Bio, which focuses on cell and gene therapy programs and cancer treatments. These transactions highlight Novo Holdings' commitment to advancing bioinformatics and related fields.


2. Almi

  • Website: almi.se
  • Type: Venture Capital
  • Headquarters: Stockholm, Stockholm, Sweden
  • Founded year: 1994
  • Headcount: 201-500
  • Number of deals in 2024: 7
  • LinkedIn: almi-ab

Almi AB is a financial services company based in Stockholm, Sweden, founded in 1994. It specializes in providing loans, risk capital, and business development support to small and medium-sized enterprises (SMEs) in Sweden, aiming to enhance their growth and competitiveness through tailored financial solutions and guidance. Almi has been involved in several notable transactions in the bioinformatics sector, including investments in SARomics Biostructures, which focuses on biostructure analysis, and Countagen, which is engaged in genomic data analysis. Additionally, Almi participated in the funding round for Aligned Bio, a company developing sequencing technology, further demonstrating their engagement in the bioinformatics space. These investments highlight Almi's commitment to supporting innovative companies within the bioinformatics industry.


3. HealthCap

  • Website: healthcap.eu
  • Type: Venture Capital
  • Headquarters: Stockholm, Stockholm, Sweden
  • Founded year: 1996
  • Headcount: 11-50
  • Number of deals in 2024: 5
  • LinkedIn: healthcap

HealthCap is a venture capital firm based in Stockholm, Sweden, founded in 1996. The firm specializes in the life sciences sector, investing in and supporting innovative companies that are developing breakthrough therapies for diseases with high unmet medical needs. HealthCap's portfolio includes notable transactions such as their investment in Aro Biotherapeutics, which focuses on Centyrin-targeted genetic medicines and has raised significant funding to advance its pipeline of therapies, including those for autoimmune disorders. Additionally, HealthCap has been involved in funding rounds for companies like Gyros and Precirix, which, while primarily focused on biotechnology and oncology, also contribute to the broader life sciences landscape that intersects with bioinformatics. Their expertise and investments in companies that leverage genetic and therapeutic innovations position them as a relevant player in the bioinformatics space.


4. Hadean Ventures

  • Website: hadeanventures.com
  • Type: Venture Capital
  • Headquarters: Oslo, Oslo, Norway
  • Founded year: 2014
  • Headcount: 11-50
  • Number of deals in 2024: 1
  • LinkedIn: hadean-ventures

Hadean Ventures is a venture capital firm based in Oslo, Norway, founded in 2014. The firm specializes in the life sciences sector, managing approximately EUR 230 million in assets. Hadean Ventures focuses on investing in healthcare startups to support the development of innovative medical solutions. Notable transactions include their participation in the Series A financing of Ribbon Biolabs, which is involved in biotechnological advancements, and their support for SAGA Diagnostics, a company that is commercializing ultrasensitive cancer liquid biopsies. Additionally, Hadean Ventures has invested in Complement Therapeutics, which is developing gene therapies, further showcasing their commitment to bioinformatics and healthcare innovation. Their portfolio reflects a strong alignment with the bioinformatics industry, making them a significant player in this space.


5. Industrifonden

  • Website: industrifonden.com
  • Type: Venture Capital
  • Headquarters: Stockholm, Stockholm, Sweden
  • Founded year: 1979
  • Headcount: 11-50
  • Number of deals in 2024: 9
  • LinkedIn: industrifonden

Industrifonden is a venture capital fund based in Stockholm, Sweden, founded in 1979. The fund specializes in investing in early-stage companies, particularly in the fields of Deep Tech, Life Science, and Transformative Tech. Industrifonden provides financial support and strategic guidance to startups, helping them scale their innovative solutions. Notably, they have invested in companies relevant to bioinformatics, such as Pixelgen Technologies, which raised $7.3 million to support its spatial proteomics tool, and Asgard Therapeutics, which raised significant funding for its therapeutic developments. Their involvement in these transactions highlights their commitment to fostering advancements in the life sciences, making them a significant player in the bioinformatics investment landscape.


6. EQT Group

  • Website: eqtgroup.com
  • Type: Private Equity
  • Headquarters: Stockholm, Stockholm, Sweden
  • Founded year: 1994
  • Headcount: 1001-5000
  • Number of deals in 2024: 30
  • LinkedIn: eqt-partners

EQT Group is a prominent investment firm based in Stockholm, Sweden, specializing in private equity, infrastructure, real estate, growth equity, and venture capital. Founded in 1994, EQT serves institutional investors by providing expertise in managing diverse investment portfolios across multiple sectors and geographies. The firm has made significant investments in the bioinformatics and health technology sectors, including the acquisition of Aldevron, a leading supplier of plasmid DNA for gene therapies, and Certara, a health technology company focused on drug development. Additionally, EQT has invested in SPT Labtech, a laboratory automation company, and participated in funding rounds for companies like Xilis and Mabtech, further showcasing their engagement in the bioinformatics landscape.


7. Sunstone Life Science Ventures


Sunstone Life Science Ventures is a venture capital firm based in Copenhagen, Denmark, founded in 2007. The firm specializes in investments in early-stage life science companies, focusing on developing and expanding innovations in therapeutics, medical technology, and diagnostics. Sunstone provides funding and business development support to help its portfolio companies navigate the path from research to market. Notable transactions include leading a €57 million Series A financing in Kynexis, a precision therapeutics biotech targeting brain diseases, and a $10.9 million Series A investment in Resalis Therapeutics. These investments highlight Sunstone's engagement in innovative life science solutions that may incorporate bioinformatics methodologies, particularly in precision medicine and therapeutic development.


8. Eir Ventures

  • Website: eirventures.eu
  • Type: Venture Capital
  • Headquarters: Stockholm, Stockholm, Sweden
  • Founded year: 2020
  • Headcount: 1-10
  • Number of deals in 2024: 2
  • LinkedIn: eir-ventures

Eir Ventures is a venture capital firm based in Stockholm, Sweden, founded in 2020. The firm specializes in the life sciences sector, providing funding and support to innovative companies focused on developing new medical therapies. Eir Ventures aims to address unmet medical needs and enhance patient care through strategic investments. Notably, they have participated in several relevant transactions, including a Series A funding round for Moleculent, which raised $26 million, and a funding round for ArgusEye, which raised €2.8 million to support the development of their sensor system platform designed to accelerate biotherapeutic development. Their investment in Scenic Biotech, which raised $31 million in Series A funding, further emphasizes their commitment to advancing technologies that can impact the life sciences and bioinformatics fields.


9. Chalmers Ventures


Chalmers Ventures is a venture builder and tech investor based in Sweden, founded in 2015. They focus on deep tech innovations and support researchers and entrepreneurs in commercializing their technology through various programs, providing business guidance, financing, and community networking. In 2024, they participated in a seed round for LanteRNA, a company that has raised funds for its bioinformatics-related projects, indicating their engagement in the bioinformatics sector. Additionally, they have invested in Vitroprobe Analytics AB, which also operates in the bioinformatics field. Their model emphasizes active ownership and investment in startups, helping them scale and succeed in the market, particularly in areas that include bioinformatics.


10. Novo Nordisk

  • Website: novonordisk.com
  • Type: Corporate
  • Headquarters: Denmark
  • Founded year: 1923
  • Headcount: 10001+
  • Number of deals in 2024: 4
  • LinkedIn: novo-nordisk

Novo Nordisk A/S is a leading multinational pharmaceutical company based in Denmark, founded in 1923. The company specializes in diabetes care and treatments for other chronic diseases, developing a range of medications including semaglutide and various insulin products. In recent years, Novo Nordisk has actively engaged in investments that intersect with bioinformatics and biotechnology. Notably, they participated in a $401 million Series D funding round for ElevateBio, a company focused on advancing technology platforms for gene editing and cell therapy, which are heavily reliant on bioinformatics. Additionally, their investment in Affimed Therapeutics, which is working on therapeutic antibody technology, further demonstrates their commitment to innovative biotechnologies. Novo Nordisk's acquisition of Cardior Pharmaceuticals for up to 1.025 billion Euros also highlights their strategic interest in expanding their portfolio in the biopharmaceutical sector, which often involves bioinformatics in drug development and patient care. Overall, Novo Nordisk's investment activities reflect a significant engagement with bioinformatics-related technologies.


11. Summa Equity

  • Website: summaequity.com
  • Type: Private Equity
  • Headquarters: Stockholm, Stockholm, Sweden
  • Founded year: 2016
  • Headcount: 51-200
  • Number of deals in 2024: 6
  • LinkedIn: summa-equity

Summa Equity is a private equity firm based in Stockholm, Sweden, founded in 2016. The firm specializes in thematic investments that address global challenges, with a strong emphasis on sustainable investment solutions across various sectors, including resource efficiency and technology. Summa Equity's investment strategy is characterized by a commitment to aligning financial returns with positive societal impact. In the life sciences sector, they have made significant investments, including the acquisition of Olink Proteomics for $1.1 billion, which enhances their portfolio in the life sciences. They also acquired PierianDx, a company focused on genomic data interpretation, and Sengenics, a functional proteomics company, indicating their interest in bioinformatics and related technologies. Additionally, their investment in Axion BioSystems, which specializes in tools for drug discovery, further underscores their focus on advancing the life sciences and bioinformatics fields.


12. Flerie

  • Website: flerie.com
  • Type: Venture Capital
  • Headquarters: Stockholm, Stockholm, Sweden
  • Founded year: 2011
  • Headcount: 1-10
  • Number of deals in 2024: 2
  • LinkedIn: flerie

Flerie is a venture capital firm based in Stockholm, Sweden, founded in 2011. The firm specializes in life sciences, focusing on biotech and pharmaceutical investments. With a portfolio of over 30 companies, Flerie provides resources and expertise to navigate the challenges of drug development. They have been involved in several notable transactions, including a financing round for Strike Pharma, which aims to accelerate clinical trials for its drug candidates. Additionally, Flerie led a funding round for Amarna Therapeutics, a company developing its SVac platform for clinical studies, and participated in funding rounds for Prokarium, which is working on microbial immunotherapy and innovative vaccine development. Flerie's investments primarily span Europe, Israel, and the US, aiming to create long-term value through strategic investments in life sciences.


13. Karolinska Development


Karolinska Development is a venture capital firm based in Solna, Stockholm, Sweden, founded in 2003. The firm specializes in the life sciences sector, focusing on investing in innovative pharmaceutical and medtech companies. They provide portfolio management and research support to their investments, catering to investors and organizations in the healthcare industry looking to capitalize on advancements in life sciences. Notable transactions include investments in Cellectricon, which raised $7,046,952 in Series B funding in 2004, and Pretzel Therapeutics, which raised $72,500,000 in Series A funding in 2022. These investments indicate a commitment to supporting innovative companies that may intersect with bioinformatics, particularly in drug development and research applications.


14. Seed Capital Denmark

  • Website: seedcapital.dk
  • Type: Venture Capital
  • Headquarters: Frederiksberg, Frederiksberg, Denmark
  • Founded year: 2004
  • Headcount: 1-10
  • Number of deals in 2024: 5
  • LinkedIn: seed-capital-denmark

Seed Capital Denmark is a venture capital firm based in Copenhagen, specializing in providing seed funding and advisory services to technology startups in Denmark. Founded in 2004, the firm has a strong track record of successful investments, particularly in sectors such as SaaS and Fintech. However, it has also made significant investments in the healthcare and pharmaceutical sectors, which are relevant to bioinformatics. For instance, Seed Capital led a €5 million seed funding round for Abzu, a startup focused on pharmaceutical drug discovery and AI applications, highlighting its commitment to advancing technology in the healthcare space. Additionally, the firm has invested in Oncology Venture, which is involved in drug development, and Curasight A/S, which has raised funds for its innovative healthcare solutions. These transactions demonstrate Seed Capital's engagement with companies that operate at the intersection of technology and healthcare, making it a relevant player in the bioinformatics investment landscape.


15. Voima Ventures

  • Website: voimaventures.com
  • Type: Venture Capital
  • Headquarters: Helsinki, Uusimaa, Finland
  • Founded year: 2019
  • Headcount: 11-50
  • Number of deals in 2024: 11
  • LinkedIn: voima-ventures

Voima Ventures is a venture capital firm based in Helsinki, Finland, founded in 2019. The firm specializes in funding early-stage science-based innovations and deep tech ventures, with a focus on life sciences and advanced manufacturing. Voima Ventures supports startups by providing capital and expertise to help them scale their solutions for global challenges. Notably, they have participated in several relevant transactions in the bioinformatics context, including investments in Finnadvance, a biotechnology startup, and NADMED, a healthtech company. Their investment in ArgusEye, which develops a sensor system platform for biotherapeutic development, further highlights their engagement in the bioinformatics space. Voima Ventures primarily operates in the Nordic and Baltic regions, making them a significant player in the early-stage investment landscape for life sciences innovations.


16. Birk Venture

  • Website: birkventure.no
  • Type: Corporate
  • Headquarters: Oslo, Oslo, Norway
  • Founded year: 2010
  • Headcount: 1-10
  • LinkedIn:

Birk Venture is an investment company based in Oslo, Norway, founded in 2010. It specializes in the life sciences sector, focusing on providing capital and strategic support to early-stage companies with innovative healthcare technologies. Their investment portfolio includes notable transactions such as Nextera, which raised funds in a seed round in 2010, and Circio, which secured over $2 million in a Series A round in 2012. More recently, they participated in funding rounds for Accession Therapeutics, which raised significant amounts in both seed and Series A rounds, indicating their commitment to advancing healthcare innovations. Additionally, they invested in Zelluna Immunotherapy, further showcasing their focus on life sciences. While not all transactions are directly related to bioinformatics, their overall investment strategy suggests a strong alignment with the sector.


17. Inventure

  • Website: inventure.vc
  • Type: Venture Capital
  • Headquarters: Helsinki, Uusimaa, Finland
  • Founded year: 2005
  • Headcount: 11-50
  • Number of deals in 2024: 9
  • LinkedIn: inventure

Inventure is a venture capital firm based in Helsinki, Uusimaa, Finland, founded in 2005. The firm focuses on backing ambitious Nordic and Baltic founders, providing venture capital investment and portfolio management services to early-stage tech startups. Inventure has been involved in several notable transactions, particularly in the bioinformatics context. They participated in funding rounds for Blueprint Genetics, a Finnish company specializing in genetic testing, which raised significant amounts to support its international expansion and development. Additionally, Inventure invested in Abzu, a software startup that aims to enhance pharmaceutical drug discovery through AI, showcasing their commitment to supporting innovative solutions in the bioinformatics and healthcare sectors. With a total of 9 investments in 2024, Inventure continues to play an active role in the tech startup ecosystem, including areas relevant to bioinformatics.


18. Cellink


Cellink is a corporate investor based in Sweden, founded in 2016, with a focus on biotechnology, particularly in 3D bioprinting and biomaterials. They provide innovative bioprinters and bioinks to researchers and organizations in the life sciences sector, facilitating advancements in drug discovery, personalized medicine, and regenerative medicine. In recent years, Cellink has made several strategic acquisitions to enhance its portfolio. Notably, they acquired Visikol, a healthcare imaging technology company, for up to $19.5 million, which will bolster their capabilities in imaging and analysis relevant to bioinformatics. Additionally, their acquisition of MatTek Corporation for $68 million, a specialist in in-vitro technology, aims to advance research into cruelty-free drug testing models, further integrating bioinformatics into their operations. These transactions highlight Cellink's commitment to expanding its influence in the life sciences and bioinformatics sectors.



Bioinformatics Insights: Key Investors in the Nordics


InvestorHeadquarterSizeFoundedDeals 2024
Novo HoldingsHellerup, Denmark51-200199945
AlmiStockholm, Stockholm, Sweden201-50019947
HealthCapStockholm, Stockholm, Sweden11-5019965
Hadean VenturesOslo, Oslo, Norway11-5020141
IndustrifondenStockholm, Stockholm, Sweden11-5019799
EQT GroupStockholm, Stockholm, Sweden1001-5000199430
Sunstone Life Science VenturesCopenhagen, Denmark1-1020071
Eir VenturesStockholm, Stockholm, Sweden1-1020202
Chalmers VenturesSweden11-50201526
Novo NordiskDenmark10001+19234
Summa EquityStockholm, Stockholm, Sweden51-20020166
FlerieStockholm, Stockholm, Sweden1-1020112
Karolinska DevelopmentSolna, Stockholm, Sweden1-1020033
Seed Capital DenmarkFrederiksberg, Frederiksberg, Denmark1-1020045
Voima VenturesHelsinki, Uusimaa, Finland11-50201911
Birk VentureOslo, Oslo, Norway1-1020100
InventureHelsinki, Uusimaa, Finland11-5020059
CellinkSweden201-50020160


Want to find more investors focusing on the bioinformatics industry?

If you want to find more investors that are active in the bioinformaticsindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and there are a lot more private equity, venturecapital, and corporate investors like these globally.

With Inven, you'll also get to know:

  • Deal History: Number of deals and their sizes.
  • Portfolio: Companies they've invested in.
  • Contact data: Key dealmakers, including their emails and phonenumbers.
  • ...and much more!